Cabaletta Bio Inc
CABA2.190USD
+0.010+0.46%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
200.28MMarket Cap
LossP/E TTM
More Details of Cabaletta Bio Inc Company
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Company Info
Ticker SymbolCABA
Company nameCabaletta Bio Inc
IPO dateOct 25, 2019
CEODr. Steven Nichtberger, M.D.
Number of employees161
Security typeOrdinary Share
Fiscal year-endOct 25
Address2929 Arch Street
CityPHILADELPHIA
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code19104
Phone12677593100
Websitehttps://www.cabalettabio.com/
Ticker SymbolCABA
IPO dateOct 25, 2019
CEODr. Steven Nichtberger, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Steven Nichtberger, M.D.
Dr. Steven Nichtberger, M.D.
Chief Executive Officer, President, Chairman of the Board, Co-Founder
Chief Executive Officer, President, Chairman of the Board, Co-Founder
1.35M
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Dr. David J. Chang, M.D.
Dr. David J. Chang, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Catherine Bollard, M.D.
Dr. Catherine Bollard, M.D.
Independent Director
Independent Director
--
--
Mr. Mark J. Simon
Mr. Mark J. Simon
Independent Director
Independent Director
--
--
Ms. Shawn Cline Tomasello
Ms. Shawn Cline Tomasello
Independent Director
Independent Director
--
--
Mr. Richard Conover Henriques, Jr.
Mr. Richard Conover Henriques, Jr.
Independent Director
Independent Director
--
--
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
President - Science and Technology
President - Science and Technology
--
--
Dr. Arun Das, M.D.
Dr. Arun Das, M.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Anup Marda
Mr. Anup Marda
Chief Financial Officer
Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Steven Nichtberger, M.D.
Dr. Steven Nichtberger, M.D.
Chief Executive Officer, President, Chairman of the Board, Co-Founder
Chief Executive Officer, President, Chairman of the Board, Co-Founder
1.35M
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Dr. David J. Chang, M.D.
Dr. David J. Chang, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Catherine Bollard, M.D.
Dr. Catherine Bollard, M.D.
Independent Director
Independent Director
--
--
Mr. Mark J. Simon
Mr. Mark J. Simon
Independent Director
Independent Director
--
--
Ms. Shawn Cline Tomasello
Ms. Shawn Cline Tomasello
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bain Capital Life Sciences Investors, LLC
10.58%
Adage Capital Management, L.P.
9.65%
T. Rowe Price Investment Management, Inc.
7.43%
Jennison Associates LLC
6.58%
Cormorant Asset Management, LP
5.47%
Other
60.29%
Shareholders
Shareholders
Proportion
Bain Capital Life Sciences Investors, LLC
10.58%
Adage Capital Management, L.P.
9.65%
T. Rowe Price Investment Management, Inc.
7.43%
Jennison Associates LLC
6.58%
Cormorant Asset Management, LP
5.47%
Other
60.29%
Shareholder Types
Shareholders
Proportion
Investment Advisor
34.02%
Hedge Fund
31.57%
Investment Advisor/Hedge Fund
10.03%
Research Firm
4.01%
Individual Investor
1.65%
Venture Capital
0.11%
Bank and Trust
0.04%
Other
18.56%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
333
45.33M
50.39%
-18.00M
2025Q1
343
38.78M
72.92%
-24.88M
2024Q4
342
40.39M
82.63%
-20.01M
2024Q3
330
50.24M
102.85%
-12.34M
2024Q2
325
53.21M
110.27%
-11.74M
2024Q1
310
53.11M
110.79%
-5.05M
2023Q4
269
50.62M
118.36%
-623.67K
2023Q3
244
42.61M
108.50%
-4.28M
2023Q2
218
38.30M
97.94%
+637.03K
2023Q1
208
26.57M
91.08%
-5.98M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bain Capital Life Sciences Investors, LLC
2.76M
3.07%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
3.63M
4.04%
--
--
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
3.97M
4.41%
-103.98K
-2.55%
Mar 31, 2025
Jennison Associates LLC
2.43M
2.71%
-78.33K
-3.12%
Mar 31, 2025
The Vanguard Group, Inc.
2.84M
3.16%
-23.48K
-0.82%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
